Pioneer of Altered Nicotine Tobacco to Give Keynote Address at 22nd Century Group’s Annual Shareholder Meeting
April 18 2016 - 11:44AM
Business Wire
22nd Century Group, Inc. (NYSE MKT: XXII), a plant
biotechnology company that is a leader in tobacco harm reduction,
announced today that Michael P. Timko, PhD, Professor of Biology
and Public Health Sciences at The University of Virginia, will
present the keynote address at 22nd Century Group’s annual
shareholder meeting. The shareholder meeting will be held on
Saturday April 30, 2016 at 1:00PM at the Buffalo Club in downtown
Buffalo, New York. The annual meeting will be open to shareholders
of record as of the close of business on March 8, 2016.
Professor Timko is a biochemist and molecular biologist who has
studied tobacco genomics and tobacco related health issues for more
than more than 30 years. He is a pioneer in the field of altering
nicotine levels in tobacco. Professor Timko’s landmark research has
revealed a large number of novel gene targets which may lead to
important tobacco harm reduction and smoking cessation products.
Currently directing 22nd Century’s innovative Brand B high nicotine
tobacco project at the University of Virginia, Professor Timko is a
key part of the Company’s initiative to develop a new generation of
reduced-harm tobacco products.
Professor Timko’s experience is unique in the field of tobacco
harm reduction in that he works on both plant biology and human
biology. In addition to manipulating nicotine levels in tobacco
plants, his laboratory has developed human cell models for the
evaluation of risk potential in tobacco and tobacco-less
alternative products.
Professor Timko has authored or co-authored more than 150
research papers, book chapters and review articles including
seminal works on the regulation of nicotine production in tobacco
plants. His group also produced the TOBFAC database, which is the
world’s largest database of regulatory genes from tobacco.
Professor Timko’s research efforts have generated multiple US and
world-wide patents in agricultural and nutritional
biotechnology.
About 22nd Century Group, Inc.
22nd Century is a plant biotechnology company focused on
technology which allows it to increase or decrease the level of
nicotine in tobacco plants and the level of cannabinoids in
cannabis plants through genetic engineering and plant breeding. The
Company’s primary mission is to reduce the harm caused by smoking.
22nd Century currently owns or exclusively controls more than 200
issued patents and more than 50 pending patent applications around
the world. The Company’s strong IP position led to a licensing
agreement with British American Tobacco (“BAT”), the world’s second
largest tobacco company. Visit www.xxiicentury.com, for more
information.
Cautionary Note Regarding Forward-Looking Statements: This press
release contains forward-looking information, including all
statements that are not statements of historical fact regarding the
intent, belief or current expectations of 22nd Century Group, Inc.,
its directors or its officers with respect to the contents of this
press release, including but not limited to our future revenue
expectations. The words “may,” “would,” “will,” “expect,”
“estimate,” “anticipate,” “believe,” “intend” and similar
expressions and variations thereof are intended to identify
forward-looking statements. We cannot guarantee future results,
levels of activity or performance. You should not place undue
reliance on these forward-looking statements, which speak only as
of the date that they were made. These cautionary statements should
be considered with any written or oral forward-looking statements
that we may issue in the future. Except as required by applicable
law, including the securities laws of the United States, we do not
intend to update any of the forward-looking statements to conform
these statements to reflect actual results, later events or
circumstances, or to reflect the occurrence of unanticipated
events. You should carefully review and consider the various
disclosures made by us in our annual report on Form 10-K for the
fiscal year ended December 31, 2015, filed on February 18, 2016,
including the section entitled “Risk Factors,” and our other
reports filed with the U.S Securities and Exchange Commission which
attempt to advise interested parties of the risks and factors that
may affect our business, financial condition, results of operation
and cash flows. If one or more of these risks or uncertainties
materialize, or if the underlying assumptions prove incorrect, our
actual results may vary materially from those expected or
projected.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160418006209/en/
Investor Relations:IRTH CommunicationsAndrew Haag,
866-976-4784xxii@irthcommunications.comorRedington, Inc.Tom
Redington, 203-222-7399
22nd Century (AMEX:XXII)
Historical Stock Chart
From Mar 2024 to Apr 2024
22nd Century (AMEX:XXII)
Historical Stock Chart
From Apr 2023 to Apr 2024